Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized content and targeted ads, to analyze our website traffic, and to understand ...

USA News GroupNews Commentary – Despite optimism coming from the launch of Project Stargate (a $500 billion investment in AI ...

SAN DIEGO and CALGARY, AB, Feb. 19, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, continues to ...

Biotech continues to make good progress in 2025 with key regulatory and clinical advancements, reinforcing pelareorep’s ...

Amid the excitement surrounding Project Stargate—the $500 billion investment aimed at revolutionizing AI-driven ...

Oncolytics Biotech Inc shares T.ONC are trading unchanged at $1.07.

Oncolytics (ONCY) reported on progress in 2025 with key regulatory and clinical advancements, reinforcing pelareorep’s potential in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CONTINUED... Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the m ...